These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26068762)

  • 1. Surgical and Molecular Pathology of Barrett Esophagus.
    Zibadi S; Coppola D
    Cancer Control; 2015 Apr; 22(2):177-85. PubMed ID: 26068762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barrett esophagus: diagnostic challenges.
    Hagen CE; Lauwers GY; Mino-Kenudson M
    Semin Diagn Pathol; 2014 Mar; 31(2):100-13. PubMed ID: 24815936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-segment Barrett's esophagus associated with high-grade dysplasia.
    Morita K; Fujimori T; Ono Y; Masuyama H; Nakamura T; Terano A
    J Gastroenterol; 2002; 37(12):1083-5. PubMed ID: 12522544
    [No Abstract]   [Full Text] [Related]  

  • 4. [Update on Barrett esophagus and Barrett carcinoma].
    Werner M; Laßmann S
    Pathologe; 2012 Nov; 33 Suppl 2():253-7. PubMed ID: 23011020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoplastic precursor lesions in Barrett's esophagus.
    Hornick JL; Odze RD
    Gastroenterol Clin North Am; 2007 Dec; 36(4):775-96, v. PubMed ID: 17996790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiofrequency ablation and dilated columnar-lined esophagus.
    Lenglinger J; Riegler M
    Am J Gastroenterol; 2009 Oct; 104(10):2631; author reply 2632. PubMed ID: 19806096
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
    Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G
    Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia.
    Voltaggio L; Montgomery EA; Lam-Himlin D
    Arch Pathol Lab Med; 2011 Oct; 135(10):1249-60. PubMed ID: 21970480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Barrett's esophagus with dysplasia.
    Hagen JA
    Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):285-9. PubMed ID: 9263347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG; Williams L; Guernsey DL
    Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's esophagus and esophageal cancer: an overview.
    Conteduca V; Sansonno D; Ingravallo G; Marangi S; Russi S; Lauletta G; Dammacco F
    Int J Oncol; 2012 Aug; 41(2):414-24. PubMed ID: 22615011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
    Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.